Citigroup
TLIS

Citigroup’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Citigroup’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,624
Closed -$12.1K – 5943
2023
Q4 		$12.1K Sell
1,624
-3,643
-69% -$23.7K ﹤0.01% 5144
2023
Q3 		$30.3K Buy
+5,267
New +$36K ﹤0.01% 4280
2022
Q3 		– Sell
-9
Closed – – 6494
2022
Q2 		$0 Sell
9
-244
-96% -$3.86K ﹤0.01% 6820
2022
Q1 		$5K Buy
253
+8
+3% +$277 ﹤0.01% 5847
2021
Q4 		$15K Buy
245
+125
+104% +$9.35K ﹤0.01% 5482
2021
Q3 		$11K Buy
120
+74
+161% +$9.86K ﹤0.01% 5451
2021
Q2 		$8K Sell
46
-12
-21% -$2.04K ﹤0.01% 5749
2021
Q1 		$11K Buy
+58
New +$14.5K ﹤0.01% 5606

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $155M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $77.3B AUM 36.07% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.3B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return